An MGH pilot study evaluating scalp skin disruption using Follica’s proprietary Hair Follicle Neogenesis stimulation product was published in International Journal of Women’s Dermatology, demonstrating the treatment promoted hair growth in female pattern hair loss. The study endpoints included photographs, patient-reported improvement and physician-documented Sinclair score.
The pilot study, led by Maryanne M. Senna, M.D., an assistant professor of dermatology at Harvard Medical School, enrolled 11 women with mild to moderate FPHL who had been on stable existing treatments for six or more months. Patients underwent six treatments with the Follica proprietary Hair Follicle Neogenesis (HFN) device and application of a topical on-market drug on non-treatment days. The scalp treatments with the HFN device, which last just a few minutes, stimulate stem cells and enable the growth of new hair follicles. A topical drug is then applied to enhance efficacy by thickening new hair follicle